Enzo Biochem Statistics
Total Valuation
Enzo Biochem has a market cap or net worth of $26.98 million. The enterprise value is -$17.49 million.
Important Dates
The next estimated earnings date is Wednesday, March 12, 2025, after market close.
| Earnings Date | Mar 12, 2025 |
| Ex-Dividend Date | Nov 15, 2024 |
Share Statistics
Enzo Biochem has 52.24 million shares outstanding. The number of shares has increased by 3.82% in one year.
| Current Share Class | 52.24M |
| Shares Outstanding | 52.24M |
| Shares Change (YoY) | +3.82% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 20.33% |
| Owned by Institutions (%) | 21.66% |
| Float | 36.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.88 |
| Forward PS | n/a |
| PB Ratio | 0.57 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.55, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.55 |
| Quick Ratio | 2.20 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -53.36 |
Financial Efficiency
Return on equity (ROE) is -11.83% and return on invested capital (ROIC) is -9.94%.
| Return on Equity (ROE) | -11.83% |
| Return on Assets (ROA) | -7.24% |
| Return on Invested Capital (ROIC) | -9.94% |
| Return on Capital Employed (ROCE) | -20.25% |
| Revenue Per Employee | $222,897 |
| Profits Per Employee | -$167,926 |
| Employee Count | 136 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.17% in the last 52 weeks. The beta is 0.78, so Enzo Biochem's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -61.17% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 35.36 |
| Average Volume (20 Days) | 180,935 |
Short Selling Information
The latest short interest is 296,412, so 0.57% of the outstanding shares have been sold short.
| Short Interest | 296,412 |
| Short Previous Month | 299,823 |
| Short % of Shares Out | 0.57% |
| Short % of Float | 0.82% |
| Short Ratio (days to cover) | 2.56 |
Income Statement
In the last 12 months, Enzo Biochem had revenue of $30.31 million and -$22.84 million in losses. Loss per share was -$0.45.
| Revenue | 30.31M |
| Gross Profit | 13.46M |
| Operating Income | -10.51M |
| Pretax Income | 44.73M |
| Net Income | -22.84M |
| EBITDA | -9.19M |
| EBIT | -10.51M |
| Loss Per Share | -$0.45 |
Full Income StatementBalance Sheet
The company has $47.74 million in cash and $3.27 million in debt, giving a net cash position of $44.47 million or $0.85 per share.
| Cash & Cash Equivalents | 47.74M |
| Total Debt | 3.27M |
| Net Cash | 44.47M |
| Net Cash Per Share | $0.85 |
| Equity (Book Value) | 47.66M |
| Book Value Per Share | 0.91 |
| Working Capital | 36.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.88 million and capital expenditures -$739,000, giving a free cash flow of -$22.61 million.
| Operating Cash Flow | -21.88M |
| Capital Expenditures | -739,000 |
| Free Cash Flow | -22.61M |
| FCF Per Share | -$0.43 |
Full Cash Flow StatementMargins
Gross margin is 44.39%, with operating and profit margins of -34.67% and -75.34%.
| Gross Margin | 44.39% |
| Operating Margin | -34.67% |
| Pretax Margin | -23.79% |
| Profit Margin | -75.34% |
| EBITDA Margin | -30.32% |
| EBIT Margin | -34.67% |
| FCF Margin | n/a |